AzTrials
AzTrials

SarcopeniaNCT03740061

Muscle Assessment Through Ultrasound in the Evaluation of Acute Sarcopenia

An observational study of Sarcopenia, run by Universiteit Antwerpen at 1 site in Belgium.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Traditionally, muscle mass - a part of the concept of sarcopenia - is measured by computed tomography (CT) or dual-energy X-ray absorptiometry (DEXA) scan. These devices are not always easily available in clinical practice and cannot be used bedside. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Sarcopenia
What is being tested?
Ultrasonographic assessment of muscle
How many people
200 participants
Where
1 siteBelgium
Study dates
1 Jan 2019to 30 Apr 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: All participants ages 65 years or older and admitted to one of the ward of one of the centers in the given time period.

Who may be able to join

  • All participants ages 65 years AND
  • Admitted to one of the ward of one of the centers in the given time period.

Who cannot join

  • Patients on dialysis will be excluded because of possible metabolic features.
  • Individuals with paresis of the lower limbs or hemiparesis due to a stroke will be excluded because of neurological involvement that can influence the results.
  • Hypo-or hyperthyroid patients will be excluded because of the role of thyroid hormones in muscle homeostasis.
  • Pitting oedema of the legs (due to heart failure, anasarca oedema, renal failure or liver cirrhosis) or severely dehydrated patients will be excluded because fluid shifts could influence the ultrasound measurement results.
  • Because of possible previous changes in muscle mass, architecture and function, patients with systemic connective tissue disorders, myositis, calcification and ossification of muscle, systemic atrophies primarily affecting the central nervous system and demyelinating diseases of the central nervous system will be excluded.
  • Patients using chronic oral corticosteroids will be excluded.

Trial locations and contacts

1 site in 1 country.

Belgium1 site, 1 recruiting
  • ZNA Middelheim

    Antwerp, 2020

    Stany Perkisas, MD, 032803539 ext. 0032, stany.perkisas@zna.be

    Recruiting

Other trials in Belgium

About this study

Official title: The Evaluation of Acute Sarcopenia in Hospitalized Elderly: Muscle Characteristics Assessment Through Ultrasound

Traditionally, muscle mass - a part of the concept of sarcopenia - is measured by computed tomography (CT) or dual-energy X-ray absorptiometry (DEXA) scan. These devices are not always easily available in clinical practice and cannot be used bedside. An innovation in sarcopenia is the assessment of muscle mass and quality with ultrasound. Because this device is much more available and applicable in all patients, diagnosis of acute sarcopenia would be much easier with ultrasound. Moreover, if other factors that contribute to accelerated decline in muscle mass and function can be determinated, the sensiblisation and early screening for acute sarcopenia in those individuals can hopefully prevent them from declining.

Read the detailed description

Methods Study design A prospective, multicenter, international observational study will be conducted. The study is designed to determine the effect of hospitalisation due to acute illness on the changes in muscle mass and muscle function. The secondary endpoint of the study is to identify health related parameters associated with the development of acute sarcopenia.

Subjects Inclusion criteria Patients admitted between the 1st of December 2018 until the 31th of November 2019 will be eligible for inclusion. Included wards for admission are: internal medicine, acute geriatrics, orthogeriatrics and rehabilitation. Age limit will be set on 65 years and older.

Exclusion criteria Patients on dialysis will be excluded because of possible metabolic features. Individuals with paresis of the lower limbs or hemiparesis due to a stroke will be excluded because of neurological involvement that can influence the results. Hypo-or hyperthyroid patients will be excluded because of the role of thyroid hormones in muscle homeostasis. Pitting oedema of the legs (due to heart failure, anasarca oedema, renal failure or liver cirrhosis) or severely dehydrated patients will be excluded because fluid shifts could influence the ultrasound measurement results. Because of possible previous changes in muscle mass, architecture and function, patients with systemic connective tissue disorders, myositis, calcification and ossification of muscle, systemic atrophies primarily affecting the central nervous system and demyelinating diseases of the central nervous system will be excluded. Patients using chronic oral corticosteroids will be excluded.

Settings and locations The study will be a multicenter study held in different university and tertiary teaching hospitals throughout Europe.

Measurements

Patient characteristics Date of birth, gender, height and weight will be registered. If the patient is bedridden, weight can be measured through either weight chairs or weight measuring lifts. Height will be estimated using the ulna length or knee height. Date of admission and discharge will be noted. The home care setting of the patient will be registered. The main reason of hospital admission will be registered.

Comorbidities on admission will be registered through the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). The CIRS-G was designed to estimate the survival of elderly persons, assessing disease severity using a score from 0 to 4 in 14 different categories of organ systems: cardiac, vascular, hematological, respiratory, ophthalmological and otorhinolaryngological, upper gastro-intestinal, lower gastro-intestinal, hepatic and pancreatic, renal, genito-urinary, musculoskeletal and tegumental, neurological, endocrine/metabolic/breast and psychiatric. Score '0' stands for 'no problem affecting that system', score '1' stands for 'current mild problem or past significant problem', score '2' stands for 'moderate disability or morbidity', score '3' stands for 'severe problem' and score '4' stands for 'extremely severe problem'.

Laboratory values that will be checked are either nutritional through albumin and prealbumin, inflammatory through C-reactive protein (CRP) and white blood cell count, and the measurement of 25-hydroxyvitamin D (25-OH-vitamin D). Blood samples will be collected on day of admission. Laboratory values that are not expected to fluctuate strongly (albumin, pre-albumin, 25-OH-vitamin D) will be taken within the first 5 days of admission.

Muscle mass In order to obtain reliable and consistent measurements, all ultrasonography will be done by an ultrasonographist that is trained to perform the measurements proposed. For the measurements, a linear probe of 5 cm width will be used. Frequency of the beam will be set on 12 MHz.

Patients should not have had any physical exercise in the 30 minutes before the measurement. Muscles should be completely relaxed and patients should be placed in the supine position, with hips in neutral position and knees fully extended. The dominant leg will be taken for the measurements. To calculate the relative muscle thickness values, the total length of muscle will be noted.

Ultrasonographic data of the four bellies of the quadriceps muscle (rectus femoris, vastus lateralis, vastus medialis, vastus intermedius) will be taken. Measuring points will be specified according to the propositions of the SARCUS-working group. Muscle thickness, fascicle length, pennation angle, muscle cross-sectional area and echo-intensity of all muscles listed will be taken.

The first measurement will be taken as early as possible within 48 hours after admission at the latest. Follow-up measurements will be taken according to the type of ward the patient is admitted to. For patients that are expected to be hospitalized for a limited time (<5 days), the follow-up measurement will be done 3 days after initial measurement. For patients that are expected to be hospitalized for a longer time (>7 days), measurements will be repeated 7 days after initial measurement, to be repeated after another 7 days as long as the patient is hospitalized.

Muscle strength and function Muscle strength will be measured through hand grip strength using a Jamar dynamometer, using the Southampton protocol. The first measurement will be taken as early as possible within 48 hours after admission at the latest. Follow-up measurements will be taken according to the type of ward the patient is admitted to. For patients that are expected to be hospitalized for a limited time (<5 days), the follow-up measurement will be done 3 days after initial measurement. For patients that are expected to be hospitalized for a longer time (>7 days), measurements will be repeated 7 days after initial measurement, to be repeated after another 7 days as long as the patient is hospitalized. Measurement will be done directly after the ultrasonographic assessment. If feasible, muscle function will be measured through gait speed, using the 4-meter walking test at usual gait speed. In case of those bedridden, gait speed will not be measured.

In-hospital activity Registration of activity level during hospitalisation will be performed by means of pedometers in those centers that have access to these devices. Both amount of steps and step length will be noted, and total walked distance per day can hereby be calculated.

Nutritional status Nutritional state of the patient will be registered through the Mini-Nutritional Assessment - Short Form (MNA-SF). For diagnosis of malnutrition, the new Global Leadership Initiative on Malnutrition (GLIM)-criteria will be used.

Questionnaires The SARC-F and FRAIL-scale will be completed as routine screening questionnaires for sarcopenia and frailty, respectively. The SAR-QOL questionnaire will be used to evaluate the self-reported quality of life.

Statistical analysis Databases will be kept up in a Microsoft Access database. Statistical analysis will be done by using SPSS Statistics version 24. Descriptive analyses will be used for determining the clinical and demographic characteristics. A Kolmogorov-Smirnov test will be used to verify the normal distribution of the different variables. Further statistical analyses will be performed by Chi Square test, Fisher exact, Mann-Whitney U test or Fisher exact test, depending on the distribution and the nature of the variables analysed. P-values of ≤0.05 will be considered statistically significant.

Conditions
Sarcopenia
Being tested
Ultrasonographic assessment of muscle
Keywords
Ultrasound, Assessment, Acute sarcopenia, Hospitalized older people
Medical subject headings
Sarcopenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultrasonographic assessment of muscleDiagnostic test

    Ultrasonographic assessment of quadriceps muscle

Study groups in NCT03740061
Study groupRoleWhat they receive
AntwerpNot described
Receives: Diagnostic Test: Ultrasonographic assessment of muscle
BarcelonaNot described
Receives: Diagnostic Test: Ultrasonographic assessment of muscle
IstanbulNot described
Receives: Diagnostic Test: Ultrasonographic assessment of muscle
OldenburgNot described
Receives: Diagnostic Test: Ultrasonographic assessment of muscle
KrakowNot described
Receives: Diagnostic Test: Ultrasonographic assessment of muscle
BialystokNot described
Receives: Diagnostic Test: Ultrasonographic assessment of muscle
RomeNot described
Receives: Diagnostic Test: Ultrasonographic assessment of muscle
MadridNot described
Receives: Diagnostic Test: Ultrasonographic assessment of muscle
LeuvenNot described
Receives: Diagnostic Test: Ultrasonographic assessment of muscle

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change over 7 days in ultrasonographic measured muscle thickness (in centimeter) in the four bellies of the quadriceps muscle

    Change over 7 days in ultrasonographic measured muscle thickness (in centimeter) in the four bellies of the quadriceps muscle

    Measured: 7 days

  2. Change over 7 days in ultrasonographic measured muscle cross-sectional area (in square centimeter) in the four bellies of the quadriceps muscle

    Change over 7 days in ultrasonographic measured muscle cross-sectional area (in square centimeter) in the four bellies of the quadriceps muscle

    Measured: 7 days

  3. Change over 7 days in ultrasonographic measured muscle pennation angle (in degrees) in the four bellies of the quadriceps muscle

    Change over 7 days in ultrasonographic measured muscle pennation angle (in degrees) in the four bellies of the quadriceps muscle

    Measured: 7 days

  4. Change over 7 days in ultrasonographic measured muscle fascicle length (in centimeter) in the four bellies of the quadriceps muscle

    Change over 7 days in ultrasonographic measured muscle fascicle length (in centimeter) in the four bellies of the quadriceps muscle

    Measured: 7 days

  5. Change over 7 days in ultrasonographic measured muscle echo-intensity (gray values in Houndsfield units) in the four bellies of the quadriceps muscle

    Change over 7 days in ultrasonographic measured muscle echo-intensity (gray values in Houndsfield units) in the four bellies of the quadriceps muscle

    Measured: 7 days

Secondary outcomes (10)
  1. Influence of muscle thickness on muscle strength measured by hand grip strength

    Determining what the influence of (changes in) muscle thickness (in centimeter) in the four bellies of the quadriceps muscle is on muscle strength measured by hand grip strength (kg)

    Measured: 7 days

  2. Influence of muscle cross-sectional area on muscle strength measured by hand grip strength

    Determining what the influence of (changes in) muscle cross-sectional area (in square centimeter) in the four bellies of the quadriceps muscle on muscle strength measured by hand grip strength (kg)

    Measured: 7 days

  3. Influence of muscle pennation angle on muscle strength measured by hand grip strength

    Determining what the influence of (changes in) muscle pennation angle (in degrees) in the four bellies of the quadriceps muscle is on muscle strength measured by hand grip strength (kg)

    Measured: 7 days

  4. Influence of muscle fascicle length on muscle strength measured by hand grip strength (kg)

    Determining what the influence of (changes in) muscle fascicle length (in centimeter) in the four bellies of the quadriceps muscle is on muscle strength measured by hand grip strength (kg)

    Measured: 7 days

  5. Influence of muscle echo intensity on muscle strength measured by hand grip strength (kg)

    Determining what the influence of (changes in) muscle echo intensity (gray values in Houndsfield units) in the four bellies of the quadriceps muscle is on muscle strength measured by hand grip strength (kg)

    Measured: 7 days

  6. Influence of muscle thickness on muscle function measured by short physical performance battery

    Determining what the relation is between (changes in) muscle thickness (in centimeter) in the four bellies of the quadriceps muscle and muscle function measured by short physical performance battery

    Measured: 7 days

  7. Influence of muscle cross-sectional area on muscle function measured by short physical performance battery

    Determining what the influence of (changes in) muscle cross-sectional area (in square centimeter) in the four bellies of the quadriceps muscle on muscle function measured by short physical performance battery

    Measured: 7 days

  8. Influence of muscle pennation angle on muscle function measured by short physical performance battery

    Determining what the influence of (changes in) muscle pennation angle (in degrees) in the four bellies of the quadriceps muscle is on muscle function measured by short physical performance battery

    Measured: 7 days

  9. Influence of muscle fascicle length on muscle function measured by short physical performance battery

    Determining what the influence of (changes in) muscle fascicle length (in centimeter) in the four bellies of the quadriceps muscle is on muscle function measured by short physical performance battery

    Measured: 7 days

  10. Influence of muscle echo intensity on muscle function measured by short physical performance battery

    Determining what the influence of (changes in) muscle echo intensity (gray values in Houndsfield units) in the four bellies of the quadriceps muscle is on muscle function measured by short physical performance battery

    Measured: 7 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Nov 2018
  2. Study start1 Jan 2019
  3. Primary completion1 Mar 2022 (estimated)
  4. Study completion30 Apr 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03740061
Sponsor's protocol ID
SARCUS2
Status last verified
Apr 2021
First submitted
23 Oct 2018
Last updated
28 Apr 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Sarcopenia, run by Universiteit Antwerpen at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Stany Perkisas, MD (003232803539 ext. 0032, stany.perkisas@zna.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change over 7 days in ultrasonographic measured muscle thickness (in centimeter) in the four bellies of the quadriceps muscle (time frame: 7 days). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in